Advertisement

Topics

Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

2014-08-27 03:40:19 | BioPortfolio

Summary

The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Conditions

Essential Hypertension

Intervention

olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo, olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil/hydrochlorothiazide tablets, olmesartan medoxomil/hydrochlorothiazide tablets

Location

Pleven
Bulgaria

Status

Completed

Source

Daiichi Sankyo Inc.

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:40:19-0400

Clinical Trials [1204 Associated Clinical Trials listed on BioPortfolio]

Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension

The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood...

VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan Medoxomil

To evaluate the efficacy of valsartan 160 mg/HCTZ 25 mg in patients not adequately responding to monotherapy with olmesartan medoxomil 40 mg or combination therapy with olmesartan medoxomi...

Fasting Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg

The objective of this study was to investigate the bioequivalence of Mylan's olmesartan medoxomil and hydrochlorothiazide 40 mg/25 mg tablets to Sankyo's Benicar HCT® 40 mg/25 mg tablets ...

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

This study will analyse the dose-dependent effect of olmesartan medoxomil on the change in aterial stiffness in subjects with hypertension and metabolic syndrome

Fed Study of Olmesartan Medoxomil Tablets 40 mg and Benicar® Tablets 40 mg

The objective of this study was to investigate the bioequivalence of Mylan's olmesartan medoxomil 40 mg tablets to Sankyo's Benicar® 40 mg tablets following a single, oral 40 mg (1 x 40 m...

PubMed Articles [1063 Associated PubMed Articles listed on BioPortfolio]

A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone.

We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension.

Protective effect of angiotensin II receptor blocker against oxidative stress and inflammation in an oral mucositis experimental model.

The aim of this study was to evaluate the effect of Olmesartan medoxomil (Olme), an angiotensin II receptor antagonist, on oral mucositis (OM) experimental model. Methods OM was induced in hamsters wi...

Challenges in Simultaneous Determination of Hydrochlorothiazide and Ramipril in Human Plasma: Application to a Bioequivalence Study SHRHPB.

An isotope dilution selective and sensitive high-performance liquid chromatography-tandem mass spectrometry (LC-ESI-MS/MS) method has been developed for the simultaneous determination of hydrochloroth...

Hydrochlorothiazide binding to human serum albumin induces some compactness in the molecular structure of the protein: A multi-spectroscopic and computational study.

The interaction between hydrochlorothiazide (HCTZ), a diuretic drug, with human serum albumin (HSA) was investigated by different biophysical approaches such as UV absorption, circular dichroism (CD),...

Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide.

Chromosome 12q15 was identified in Genetic Epidemiology of Response Assessment (GERA) and replicated in Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) for its association with blood p...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of amlodipine besylate and olmesartan medoxomil that combines ANGIOTENSIN II TYPE I RECEPTOR ANTAGONIST and CALCIUM CHANNEL BLOCKER activities. It is used in the management of HYPERTENSION.

An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.

Tablets coated with material that delays release of the medication until after they leave the stomach. (Dorland, 28th ed)

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

More From BioPortfolio on "Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial